Development of AgPlus rapid electrochemical immunoassays for COVID-19

SARS-CoV-2或COVID-19是目前在世界各地传播的病毒。对该病毒的了解相对较少，但我们正在快速学习，显然我们需要有良好的诊断来支持隔离和治疗。已知的是，该病毒的连续间隔为4天，1-3%的人群可能是症状前但仍在传播病毒。感染后2-14天出现症状，97%的人在11.5天内出现症状。阻止这种疾病的传播和加强所有卫生保健系统更好地科普未来流行病的能力显然是一项全球性挑战，关键是对病毒或患者免疫状态进行准确快速的诊断检测。AgPlus用于检测对COVID-19病毒的特异性免疫反应的诊断检测将允许a）确认性检测（rule in rule out）在有症状的人中，理解在某些情况下，症状可能是由于细菌感染引起的B）监测那些测试呈阳性的患者的治疗效果，以确保他们有反应，并在安全时解除隔离c）有可能成为支持药物/疫苗开发的伴随诊断，以及d）确定您是否感染了COVID-19。

SARS-CoV-2 or COVID-19 is virus that is currently spreading throughout the world. Relatively little is understood about the virus but we are learning fast and it is clear that we need to have good diagnosis to support quarantine and treatment. What is known is that the virus has a serial interval of 4 days and 1-3% of the population may be pre-symptomatic but still transmitting the virus. It takes 2-14 days to show symptoms after infection with the 97% of people developing symptoms within 11.5 days. There is a clear global challenge to halt the spread of this disease and to strengthen the ability of all healthcare systems to cope better with future epidemics.Key to this is accurate fast diagnostic testing for the virus or immune status of patients. AgPlus' diagnostic assays for detecting specific immune responses to the COVID-19 virus will allow for a) confirmatory testing (rule in rule out) of those with symptoms, understanding that in some instances the symptoms may be due to bacterial infection b) monitoring treatment efficacy in those that have tested positive to ensure they are responding and when safe to release from isolation c) potential to be a companion diagnostic to support drug/ vaccine development and d) to determine if you have had a COVID-19 infection.